Hong Seng Consolidated Berhad via eMedAsia has entered into an exclusive partnership with CLEA Technology Sdn Bhd company that provides Cleadoc Virtual Covid-19 Professional RTK and PCR Screenings (“VCS”) to offer to Covid-19 screening for inbound and outbound travellers.
Through the partnership which involves exclusive backend system integrations, eMedAsia, a 60%-owned subsidiary under the Group’s healthcare arm HS Bio Group in partnership with Koperasi Persatuan Perubatan Malaysia which is, in turn, the investment arm of the Malaysia Medical Association will be able to provide Covid-19 screening services to both the inbound and outbound travellers as preparation for the next phase of border reopening.
Cleadoc VCS app allows users even if they are based in other countries to easily perform a professional pre-departure or on-arrival RTK test comfortably at any time anywhere with results verified by Medical Doctors by just following the in-app steps, designed carefully by Medical Doctors. The result generated can be used as a Pre-Departure result requirement or Malaysia On-Arrival 24 hours requirement which is in sync with the MySejahtera status update.
KOOP MMA Chairman & media Director Dr. Thirunavukarasu Rajoo said: “The recent announcement to open borders is a good move by the government to facilitate the nation’s gradual yet necessary transition to an endemic phase. Malaysia is expected to welcome more than 4 million visitors while many Malaysians are expected to travel abroad following the reopening of borders. Therefore, we are ready to help our government and fellow travellers to fulfil the latest requirements to cross borders easily be it VCS, professional RTK-Ag tests in clinics or hotels, or on-site PCR screenings.”
The app can be downloaded globally and can be used by international travellers bound to Malaysia. To date, Cleadoc had created more than 2 millions impression, screened more than 1 million tests, and has more than 200,000 active users on its platform.
